Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare blood disorder: drug targets overactive immune cells

NCT ID NCT03801434

Recruiting now Disease control Sponsor: William Shomali Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and reduce symptoms. Ten participants are being recruited, and the main goal is to measure how many respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ruxolitinib (a drug that blocks certain enzymes to reduce abnormal immune cell activity)

What this could lead to

If successful, this could provide a new treatment option for people with hypereosinophilic syndrome who do not respond to or cannot tolerate current therapies.

What could go wrong

This is a small, early-phase trial with only 10 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic eosinophilic leukemia Eosinophilia Hepatomegaly hypereosinophilic syndrome idiopathic hypereosinophilic syndrome lymphocytic hypereosinophilic syndrome myeloid/lymphoid neoplasm associated with JAK2 rearrangement Splenomegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCR-JAK2 FUSION PROTEIN EXPRESSION BLASTS 20 PERCENT OR LESS OF PERIPHERAL BLOOD WHITE CELLS BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS BLASTS MORE THAN 5 PERCENT OF PERIPHERAL BLOOD WHITE CELLS BLASTS UNDER 20 PERCENT OF BONE MARROW NUCLEATED CELLS CHRONIC EOSINOPHILIC LEUKEMIA, NOT OTHERWISE SPECIFIED EOSINOPHILIA HEPATOMEGALY HYPEREOSINOPHILIC SYNDROME JAK2 GENE MUTATION SPLENOMEGALY TEL-JAK2 FUSION PROTEIN EXPRESSION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutchinson cancer research center

    TERMINATED

    Seattle, Washington, 98109, United States

  • OHSU Knight Cancer Institute

    TERMINATED

    Portland, Oregon, 97201, United States

  • Stanford Cancer Institute Palo Alto

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Utah

    TERMINATED

    Salt Lake City, Utah, 84112, United States